Table 1 Socio-demographic and clinical characteristics (n = 1021)
Variable | Mild AD (n = 734, 72 %) | Moderate AD (n = 287, 28 %) | p |
|---|---|---|---|
Female sex | 473/64 % | 181/63 % | 0.717 |
APOE ε4 carrier, (n = 999) | 493/69 % | 186/66 % | 0.452 |
Solitary living at baseline | 267/36 % | 88/31 % | 0.093 |
Completion rate after 3 years | 306/42 % | 78/27 % | <0.001 |
Antihypertensives/cardiac therapy | 290/40 % | 124/43 % | 0.288 |
Antidiabetics | 38/5 % | 12/4 % | 0.629 |
Asthma medication | 28/4 % | 16/6 % | 0.231 |
Thyroid therapy | 65/9 % | 20/7 % | 0.378 |
Lipid-lowering agents | 94/13 % | 24/8 % | 0.050 |
Oestrogens | 52/7 % | 17/6 % | 0.580 |
NSAIDs/acetylsalicylic acid | 221/30 % | 84/29 % | 0.820 |
Antidepressants | 183/25 % | 74/26 % | 0.810 |
Antipsychotics | 26/4 % | 21/7 % | 0.013 |
Anxiolytics/sedatives/hypnotics | 111/15 % | 37/13 % | 0.429 |
Estimated age at onset (years) | 72.3 ± 7.1 | 72.0 ± 7.8 | 0.544 |
Estimated duration of AD at baseline (years) | 2.9 ± 2.0 | 3.4 ± 2.3 | 0.005 |
Age at first assessment (years) | 75.2 ± 6.8 | 75.3 ± 7.4 | 0.788 |
Education (years) | 9.6 ± 2.6 | 9.0 ± 2.2 | <0.001 |
MMSE score at baseline | 23.4 ± 2.0 | 16.4 ± 2.2 | <0.001 |
ADAS-cog score (0–70) at baseline | 17.5 ± 6.7 | 29.3 ± 8.3 | <0.001 |
IADL score at baseline | 14.7 ± 5.0 | 19.1 ± 5.1 | <0.001 |
PSMS score at baseline | 7.2 ± 1.9 | 8.3 ± 2.9 | <0.001 |
Number of concomitant medications at baseline | 2.9 ± 2.4 | 3.0 ± 2.6 | 0.604 |
Length in the SATS (months) | 24.2 ± 12.9 | 20.4 ± 13.0 | <0.001 |
Mean dose of ChEI during the follow-up period (mg) | |||
Donepezil (n = 518)a | 6.9 ± 1.7 (48 %) | 6.9 ± 1.8 (57 %) | 0.761 |
Rivastigmine (n = 212)a | 6.2 ± 2.1 (22 %) | 6.0 ± 2.2 (17.5 %) | 0.536 |
Galantamine (n = 291)a | 15.3 ± 3.6 (30 %) | 14.7 ± 4.0 (25.5 %) | 0.198 |